V
Vladimir Tesar
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 307
Citations - 22066
Vladimir Tesar is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 48, co-authored 256 publications receiving 17061 citations. Previous affiliations of Vladimir Tesar include Charles University in Prague.
Papers
More filters
Journal ArticleDOI
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent,Martin J Landray,Christina Reith,Jonathan Emberson,David C. Wheeler,Charles R.V. Tomson,Christoph Wanner,Vera Krane,Alan Cass,Jonathan C. Craig,Bruce Neal,Lixin Jiang,Lai Seong Hooi,Adeera Levin,Lawrence Y. Agodoa,Mike Gaziano,Bertram L. Kasiske,Robert J. Walker,Ziad A. Massy,Bo Feldt-Rasmussen,Udom Krairittichai,Vuddidhej Ophascharoensuk,Bengt Fellström,Hallvard Holdaas,Vladimir Tesar,Andrzej Wiecek,Diederick E. Grobbee,Dick de Zeeuw,Carola Grönhagen-Riska,Tanaji Dasgupta,David Lewis,William G. Herrington,Marion Mafham,William Majoni,K Wallendszus,Richard H. Grimm,Terje R. Pedersen,Jonathan A. Tobert,Jane Armitage,Alex Baxter,Christopher Bray,Yiping Chen,Zhengming Chen,Michael Hill,Carol Knott,Sarah Parish,David Simpson,Peter Sleight,Alan Young,Rory Collins +49 more
TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
Journal ArticleDOI
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
Bengt Fellström,Alan G. Jardine,Roland E. Schmieder,Hallvard Holdaas,Kym M. Bannister,J.J. Beutler,Dong Wan Chae,Alejandro Chevaile,Stuart M. Cobbe,Carola Grönhagen-Riska,José Jayme Galvão de Lima,Robert L. Lins,Gert Mayer,Alan W. McMahon,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ola Samuelsson,Sandor Sonkodi,Gultekin Suleymanlar,Dimitrios Tsakiris,Vladimir Tesar,Vasil Todorov,Andrzej Wiecek,Rudolf P. Wüthrich,Mattis Gottlow,Eva Johnsson,Faiez Zannad +27 more
TL;DR: In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.
Journal ArticleDOI
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Rachel B Jones,Jan Willem Cohen Tervaert,Thomas H. Hauser,Raashid Luqmani,Matthew D. Morgan,Chen Au Peh,Caroline O. S. Savage,Mårten Segelmark,Vladimir Tesar,Pieter van Paassen,D Walsh,Michael Walsh,Kerstin Westman,David Jayne +13 more
TL;DR: A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis and was not associated with reductions in early severe adverse events.
Journal ArticleDOI
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
David Jayne,Niels Rasmussen,Konrad Andrassy,Paul A. Bacon,Jan Willem Cohen Tervaert,J. Dadoniene,Agneta Ekstrand,Gill Gaskin,Gina Gregorini,Kirsten de Groot,Wolfgang L. Gross,E. Christiaan Hagen,Eduardo Mirapeix,Erna Pettersson,Carl Siegert,Alberto Sinico,Vladimir Tesar,Kerstin Westman,Charles D. Pusey +18 more
TL;DR: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse, suggesting the duration of exposure to cycloph phosphamide may be safely reduced.
Journal ArticleDOI
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis,Myrto Kostopoulou,Alessia Alunno,Martin Aringer,Ingeborg M. Bajema,John Boletis,Ricard Cervera,Andrea Doria,Caroline Gordon,Marcello Govoni,Frédéric Houssiau,David Jayne,Marios Kouloumas,Annegret Kuhn,Janni Lisander Larsen,Kirsten Lerstrøm,Gabriella Moroni,Marta Mosca,Matthias Schneider,Josef S Smolen,Elisabet Svenungsson,Vladimir Tesar,Angela Tincani,Anne Troldborg,Ronald F van Vollenhoven,Jörg Wenzel,George Bertsias,Dimitrios T. Boumpas +27 more
TL;DR: The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion, based on emerging new evidence.